Voya Investment Management LLC Macrogenics Inc Transaction History

Voya Investment Management LLC

$79.9 Billion
Q3 2024

A detailed history of Voya Investment Management LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Voya Investment Management LLC holds 58,993 shares of MGNX stock, worth $192,317. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,993

Previous 21,323 176.66%

Holding current value

$192,317

Previous $90,000 115.56%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.0 - $5.55 $113,010 - $209,068	37,670 Added 176.66%	58,993 $194,000
Q2 2024 Dec 03, 2024	SELL	$3.31 - $18.51 $124,687 - $697,271	-37,670 Reduced 63.86%	21,323 $90,000
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $3,876 - $21,675	1,171 Added 5.81%	21,323 $90,000
Q1 2024 Dec 06, 2024	SELL	$9.77 - $21.47 $379,476 - $833,916	-38,841 Reduced 65.84%	20,152 $296,000
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $188,267 - $413,726	-19,270 Reduced 48.88%	20,152 $296,000
Q4 2023 Feb 14, 2024	SELL	$4.48 - $10.11 $56,080 - $126,556	-12,518 Reduced 24.1%	39,422 $379,000
Q3 2023 Nov 14, 2023	BUY	$4.48 - $6.19 $20,616 - $28,486	4,602 Added 9.72%	51,940 $242,000
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $7,119 - $11,619	1,541 Added 3.36%	47,338 $253,000
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $43,148 - $64,812	-8,952 Reduced 16.35%	45,797 $328,000
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $44,872 - $93,776	-13,435 Reduced 19.7%	54,749 $367,000
Q3 2022 Mar 03, 2023	BUY	$3.01 - $5.22 $40,439 - $70,130	13,435 Added 24.54%	68,184 $207,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $86,672 - $150,309	-28,795 Reduced 29.69%	68,184 $236,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $131,094 - $582,057	58,264 Added 150.49%	96,979 $286,000
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $55,589 - $115,697	6,846 Added 21.48%	38,715 $341,000
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $8,845 - $12,165	556 Added 1.78%	31,869 $511,000
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $4,737 - $6,888	240 Added 0.77%	31,313 $656,000
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $56,204 - $97,733	2,743 Added 9.68%	31,073 $834,000
Q1 2021 May 17, 2021	SELL	$18.99 - $33.2 $21,857 - $38,213	-1,151 Reduced 3.9%	28,330 $902,000
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $104,949 - $140,582	5,407 Added 22.46%	29,481 $674,000
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $184,335 - $235,925	7,466 Added 44.95%	24,074 $606,000
Q2 2020 Aug 14, 2020	SELL	$5.2 - $29.12 $30,893 - $173,001	-5,941 Reduced 26.35%	16,608 $464,000
Q4 2019 Feb 14, 2020	BUY	$7.95 - $12.27 $37,301 - $57,570	4,692 Added 26.28%	22,549 $245,000
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $21,576 - $29,308	1,487 Added 9.08%	17,857 $303,000
Q1 2019 May 15, 2019	SELL	$11.11 - $25.6 $1.87 Million - $4.31 Million	-168,323 Reduced 91.14%	16,370 $294,000
Q4 2018 Feb 14, 2019	SELL	$11.75 - $21.42 $8.56 Million - $15.6 Million	-728,285 Reduced 79.77%	184,693 $2.35 Million
Q3 2018 Nov 14, 2018	BUY	$19.26 - $23.46 $139,172 - $169,521	7,226 Added 0.8%	912,978 $19.6 Million
Q2 2018 Aug 14, 2018	BUY	$19.78 - $24.67 $10.7 Million - $13.4 Million	542,319 Added 149.22%	905,752 $18.7 Million
Q1 2018 May 15, 2018	SELL	$18.89 - $32.46 $4.04 Million - $6.94 Million	-213,748 Reduced 37.03%	363,433 $9.14 Million
Q4 2017 Feb 14, 2018	BUY	$16.19 - $20.3 $1.2 Million - $1.5 Million	74,036 Added 14.71%	577,181 $11 Million
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $7.81 Million - $9.53 Million	503,145	503,145 $9.3 Million

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.

Account

Voya Investment Management LLC Macrogenics Inc Transaction History